Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 15;16(11):1610.
doi: 10.3390/ph16111610.

Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events

Stephanie L Gu  1 , Sandy Nath  2 , Alina Markova  1   3
Affiliations
Review

Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events

Stephanie L Gu et al. Pharmaceuticals (Basel). .

Abstract

Immune-related cutaneous adverse events (ircAEs) commonly occur in patients on treatment with immune checkpoint inhibitors and can significantly reduce patient quality of life. These are often treated with immunomodulatory agents, including glucocorticoids, immunosuppressants, and biologics. While often effective at managing symptoms, these therapies can cause several adverse events which may limit their use. In addition, immunomodulatory agents should be used with particular caution in patients receiving immunotherapy, as the efficacy of the oncologic regimen may potentially be undermined. In this review, we summarize the safety of systemic therapies that are used in the management of ircAEs, with a particular focus on the resultant risk of secondary tumor progression in patients with active cancer.

Keywords: biologics; immune-related cutaneous adverse events; safety.

PubMed Disclaimer

Conflict of interest statement

S.N. has equity ownership in Merck and Gilead. A.M. receives research funding from Incyte Corporation and Amryt Pharma; consults for ADC Therapeutics, Alira Health, Protagonist Therapeutics, OnQuality, and Janssen; and receives royalties from UpToDate. S.L.G. has no conflicts to disclose.

Similar articles

See all similar articles

Cited by

References

    1. Geisler A.N., Phillips G.S., Barrios D.M., Wu J., Leung D.Y.M., Moy A.P., Kern J.A., Lacouture M.E. Immune checkpoint inhibitor-related dermatologic adverse events. J. Am. Acad. Dermatol. 2020;83:1255–1268. doi: 10.1016/j.jaad.2020.03.132. - DOI - PMC - PubMed
    1. Robesti D., Nocera L., Belladelli F., Schultz J.G., Fallara G., Marandino L., Raggi D., Montorsi F., Msaouel P., Necchi A., et al. The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: Analysis of individual patient data from IMvigor210 and IMvigor211 trials. BJU Int. 2023 doi: 10.1111/bju.16121. - DOI - PubMed
    1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Management of Immunotherapy-Related Toxicities. [(accessed on 1 April 2023)]. Available online: https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf.
    1. Clore J.N., Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr. Pract. 2009;15:469–474. doi: 10.4158/EP08331.RAR. - DOI - PubMed
    1. Rao Kondapally Seshasai S., Kaptoge S., Thompson A., Di Angelantonio E., Gao P., Sarwar N., Whincup P.H., Mukamal K.J., Gillum R.F., Holme I., et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N. Engl. J. Med. 2011;364:829–841. doi: 10.1056/NEJMoa1008862. - DOI - PMC - PubMed

LinkOut - more resources